Effect of methadone maintenance treatment on heroin craving, a literature review

Journal of Addictive Diseases

Volumn 30, Issue 1, 2011, Pages 27-38

  Fareed, Ayman ^a,b   Vayalapalli, Sreedevi ^a   Stout, Steven ^b   Casarella, Jennifer ^a   Drexler, Karen ^a   Bailey, Stephen P ^c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELON UNIVERSITY   (United States)

Author keywords

craving; literature review; Methadone maintenance

Indexed keywords

DIAMORPHINE; METHADONE;

ARTICLE; DRUG EFFECT; HEROIN DEPENDENCE; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METHADONE TREATMENT; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BEHAVIOR, ADDICTIVE; HEROIN DEPENDENCE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT;

EID: 78651347789     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2010.531672     Document Type: Article

References (61)

1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193: 80-4.
2. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966; 66: 2011-7.
3. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med 1966; 118:304-9.
4. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin selfadministration in opioid-dependent volunteers. Addiction 2005; 100:1496-509.
5. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioiddependent humans. Psychopharmacology (Berl) 2002;161:202-12. Epub 2002 Mar 13.
6. Marsch LA. The efficacy ofmethadone maintenance interventions in reducing illicit opiate use, HIV risk behavior, and criminality: a meta-analysis. Addiction 1998; 93:515-32.
7. Farre M, Mas A, Torrens M, Moreno V, Caḿi J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002; 65:283-90.
8. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.AmJ Public Health 1995; 85:83-8.
9. Sinha R, Catapano D, OMalley S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology 1999; 142:343-51.
10. Sinha R, Fuse T, Aubin LR, OMalley S. Psychological, stress drug-related cues and cocaine craving. Psychopharmacology 2000; 152:140-8.
11. Tiffany ST. Cognitive concepts of craving. Alcohol Res.Health 1999; 23:215-24.
12. Somoza E, Baker S, Locastro J, Mezinskis J, Simon S, Tracy K. The Brief Substance Craving Scale: measuring craving in clinical trials. Poster presented at the annual meeting of the College on Problems of Drug Dependence, Acapulco, Mexico, June 12-17, 1999.
13. Langleben D, Ruparel K, Elman I Busch-Winokur, S, Pratiwadi R, Loughead J, OBrien C, Childress A. Acute effect of methadone maintenance dose on brain fMRI response to heroin-related cues. Am J Psychiatry 2008; 165:3
14. Shi J, Zhao L, Epstein D, Zhang X, Lu L. Longterm methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers. Pharmacol Biochem Behav 2007; 87:141-5.
15. Childress A, McLellan T, OBrien C. Conditioned responses in a methadone population: a comparison of laboratory, clinic, and natural settings. J Subst Abuse Treat 1986; 3:173-9.
16. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. New York: Springer-Verlag, 1991.
17. Eissenberg T, Bigelow GE, Strain, EC, Walsh SL, Brooner RK, Stitzer ML, Johnson RE. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: Arandomized clinical trial. JAMA1997; 277:1945- 51.
18. Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. Arch Gen Psychiatry 1980: 37: 908-11.
19. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract 2009; 15:227-34.
20. Fareed A, RobertsM, Sleboda M, Casarella J, Amar R, Drexler K. High dose versus moderate dose methadone maintenance, is there a better outcome. J Addict Dis 2009; 28:399-405.
21. Shi J, Zhao L, Copersino M, Fang Y, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 2008; 579:160-6.
22. Barta W, Kurth M, Stein M, Tennen H, Kiene S. Craving and self-efficacy in the first five weeks of methadone maintenance therapy: a daily process study. J Stud Alcohol Drugs 2009; 70:735-40.
23. Greenwald M. Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations. Exp Clin Psychopharmacol 2002; 10:39-46.
24. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slowrelease morphine and methadone for opioid maintenance therapy. Addiction 2005; 100:1101-9.
25. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-7.
26. Ilgen M, Jain A, Kim H, Trafton J. The effect of stress on craving for methadone depends on the timing of last methadone dose. Behav Res Ther 2008; 46:1170-5.
27. Walter M, Wiesbeck G, Bloch N, Aeschbach S, Olbrich H, Seifritz E, D̈ursteler-MacFarland K. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: A pilot study. European Neuropsychopharmacology 2008; 18:390-3.
28. Curran H, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: a doubleblind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction 1999; 94:665-74.
29. De Vos J, Ufkes J, Vandenbrink W, Vanbrussel G, Wolff F. Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant. Addictive Behaviors 1999; 24:707-13.
30. Curran V, Kleckham J, Bearn J, Strang J, Wanigaratne S. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology 2001; 154:153-60.
31. Dawe S, Gray J. Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Drug Alcohol Depend 1995; 39:207-12.
32. Mattick R, Ali R , White J, OBrien S,Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98:441-52.
33. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol Depend 1993; 33:105-17.
34. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23-7.
35. Roszell DK, Calsyn DA.Methadone dosage: patient characteristics and clinical correlates. Int J Addict 1986; 21:1233-46.
36. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290-7.
37. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88:34-9.
38. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000; 57:395-404.
39. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000-5.
40. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713-20.
41. Banys P, Tusel DJ, Sees KL, Reilly PM, Delucchi KL. Low (40 mg) versus high (80 mg) dose methadone in a 180-day heroin detoxification program. J Subst Abuse Treat 1994; 11:225-32.
42. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-5.
43. Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher dose methadone. J Psychoactive Drugs 1999; 31:95-102.
44. Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dosemethadone. J Addict Dis 2002; 21(3):1-12.
45. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Methadone maintenance dosing guidelines for opioid dependence: a literature review. Journal ofAddictive Diseases 2010; 29:1-14.
46. Fareed A, Vayalapalli S, Byrd Sellers J, Casarella J, Drexler K, Amar J, Cox J, Shaw-Lutchman T. Onsite QTc interval screening for patients in methadone maintenance treatment. Journal of Addictive Diseases 2010; 29: 15-22.
47. Fareed A, Musselman D, Byrd-Sellers J, Vayalapalli S, , Casarella C, Drexler K Phillips L. On-site basic health screening and brief health counseling of chronic medical conditions for veterans in methadone maintenance treatment. J Addict Med 2010; 4:160-6.
48. Routhier DD, Katz KD, Brooks DE. QTc prolongation and Torsades De Pontes associated with methadone therapy. J Emerg Med 2007; 32:275-8.
49. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137:501-4.
50. Cruciani RA. Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage 2008; 36:545-52. [Epub 2008 Apr 28].
51. Peles E, Bodner G, Kreek MJ, Rados V, AdelsonM. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007; 102:289-PMID: 17222284]
52. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499-506. [PMID: 14527710].
53. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11:44-9. [PMID: 15608471]
54. EhretGB,VoideC,Gex-Fabry M, Chabert J, ShahD, Broers B, Piguet V,Musset T, Gaspoz JM, Perrier A, Dayer P, Desmeules JA. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280-7. [PMID: 16801510]
55. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007; 93:1051-5. [PMID: 17344330]
56. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29:385-91. [PMID: 15857742]
57. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915-8. [PMID: 15781034]
58. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802-5. [PMID: 12820821]
59. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-95.
60. Oda Y, Kharasch ED. Metabolism ofmethadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presysternic clearance and bioactivation. J Pharmacol Exp Ther 2001; 298:1021-32.
61. Li Y. Interindividual variability of methadone response: impact of genetic polymorphisms. Mol Diagn Ther 2008; 12:109-24.